Table 2 Basic features of the included study (2)
Studies | Interventions | Outcomes | Course | Adverse reactions | |
|---|---|---|---|---|---|
Experimental group | Control group | ||||
Daniels CE 2010 [21] | Imatinib 600 mg /day | Placebo | All cause mortality,Serious adverse events,FVC(L) | 96W | Described |
Homma S 2012 [44] | N-acetylcysteine 704.8 mg /day | No treatment (or Placebo) | FVC(L) | 48W | Described |
Jackson RM 2010 [20] | Sildenafil 60 mg /day | Placebo | FVC (%) | 6M | Described |
King TE Jr(ASCEND)2014 [12] | Pirfenidone 2403 mg/day | Placebo | All cause mortality,Serious adverse events,FVC≥10% | 52W | Described |
King TE Jr(BUILD-1)2008 [39] | Bosentan 250 mg/day | Placebo | All cause mortality,Serious adverse events | 12M | Described |
King TE Jr(BUILD-3)2011 [40] | Bosentan 250 mg/day | Placebo | All cause mortality,Serious adverse events,FVC(L) | 1Y | Described |
Lancaster L 2020 [35] | Nintedanib 300 mg /day | Placebo | All cause mortality,Serious adverse events,FVC(L),FVC (%),FVC≥10% | 6M | Described |
Maher TM(FLORA)2018 [23] | GLPG1690 600 mg /day | Placebo | Serious adverse events,FVC(L) | 12W | Described |
Maher TM(INMARK)2019 [36] | Nintedanib 300 mg /day | Placebo | Serious adverse events,FVC(L) | 12W | Described |
Martinez FJ 2014 [24] | N-acetylcysteine 1800mg /day | Placebo | All cause mortality,Serious adverse events | 60W | Described |
Noble PW(CAPACITY 004)2011 [37] | Pirfenidone 2403 mg/day | Placebo | All cause mortality,Serious adverse events,FVC (%),FVC≥10% | 72W | Described |
Noble PW(CAPACITY 006)2011 [37] | Pirfenidone 2403 mg/day | Placebo | All cause mortality,Serious adverse events,FVC (%),FVC≥10% | 72W | Described |
Noth I 2012 [25] | Warfarin (1 mg and 2.5 mg)/day | Placebo | All cause mortality,Serious adverse events,FVC(L),FVC (%),FVC≥10% | 48W | Described |
Raghu G 2018 [22] | PRM-151 10 mg/kg/4 weeks | Placebo | Serious adverse events | 28W | Described |
Raghu G(ARTEMIS-IPF)2013 [26] | Ambrisentan 10 mg/day | Placebo | All cause mortality,Serious adverse events,FVC (%),FVC≥10% | 84W | Described |
Raghu G(MUSIC)2013 [41] | Macitentan 10 mg /day | Placebo | All cause mortality,Serious adverse events,FVC(L) | 12M | Described |
Raghu G(RAINIER)2017 [42] | Simtuzumab 125 mg/7 days | Placebo | All cause mortality,Serious adverse events | 82W | Described |
Richeldi L 2020 [18] | Pamrevlumab 30 mg/kg/3 weeks | Placebo | All cause mortality,Serious adverse events,FVC(L),FVC (%),FVC≥10% | 48W | Described |
Richeldi L(INPULSIS-1) 2014 [13] | Nintedanib 300 mg /day | Placebo | All cause mortality,Serious adverse events,FVC≥10% | 52W | Described |
Richeldi L(INPULSIS-2) 2014 [13] | Nintedanib 300 mg /day | Placebo | All cause mortality,Serious adverse events,FVC≥10% | 52W | Described |
Richeldi L(TOMORROW)2011 [14] | Nintedanib 300 mg /day | Placebo | All cause mortality,Serious adverse events,FVC(L),FVC (%) | 52W | Described |
Taniguchi 2010 [38] | Pirfenidone 1800 mg/day | Placebo | All cause mortality | 52W | Described |
van den Blink B 2016 [43] | PRM-151 1, 5 or 10 mg/kg/days 1, 3, 5, 8 and 15 | Placebo | FVC(L),FVC (%) | 57D | Described |
Zisman DA(STEP-IPF)2010 [19] | Sildenafil 60 mg /day | Placebo | All cause mortality,Serious adverse events,FVC (%) | 12W | Described |